Cosciens Biopharma Files 6-K for October 2024

Ticker: CSCIF · Form: 6-K · Filed: Oct 1, 2024 · CIK: 1113423

Sentiment: neutral

Topics: reporting, foreign-private-issuer

TL;DR

Cosciens Biopharma (fka Aeterna Zentaris) filed a 6-K, confirming 20-F reporting for October.

AI Summary

Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on October 1, 2024, for the month of October 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The principal executive office is located in Toronto, Ontario, Canada.

Why It Matters

This filing serves as an update for investors regarding the company's status as a foreign private issuer and its reporting obligations with the SEC.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new material financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of October 2024.

What is the current name of the company filing this report?

The current name of the company is COSCIENS Biopharma Inc.

What were the former names of COSCIENS Biopharma Inc.?

The company was formerly known as Aeterna Zentaris Inc. and AETERNA LABORATORIES INC.

Under which form will the registrant file its annual reports?

The registrant indicates it will file annual reports under cover of Form 20-F.

Where is the principal executive office of COSCIENS Biopharma Inc. located?

The principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.

Filing Stats: 312 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-10-01 17:29:05

Filing Documents

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE Ai-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number: 001-38064 COSCIENS Biopharma Inc. (Translation of registrant’s name into English) c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Exhibit 99.1 included with this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 (No. 333-224737 , No. 333-210561 , No. 333-200834 and No. 333-279844 ) (collectively, the “Registration Statements”) and shall be deemed to be a part thereof from the date on which this Report on Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. The information contained on any websites referenced in Exhibit 99.1 included with this Report on Form 6-K is not incorporated by reference or deemed to be a part of this Report on Form 6-K or any of the Registration Statements. DOCUMENTS INDEX Exhibit Description 99.1 COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COSCIENS Biopharma Inc. Date: October 1, 2024 By: /s/ Giuliano La Fratta Giuliano La Fratta Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing